Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.
diagnosed with cancer1 between 01/01/2004 and 31/12/2018
<17 years old at diagnosis
treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF
alive
Cancer diagnosis for controls
Child and adolescent female patients included in the Paediatrics Late Effects Project. Controls will be age-, sex- and socio-economic-matched individuals starting with the siblings of the survivors. Belgian (http://statbel.fgov.be/en) public demographic, socioeconomic and birth registries will be used to exclude any bias in controls recruitment.
Case-control
Cross-sectional
Not listed
The index of fertility
having children among survivors in compared with controls
The rate of menopause and POI
Number of participants in POI
The rate of premature or delayed puberty
Number of participants with premature/delayed puberty
The rate of negative pregnancy outcome (miscarriage, medical abortion, stillbirth or birth
Number of participants with pregnancy problems
Click on the lead sponsor to view all of their trials.
Centre Hospitalier Universitaire de Liege
Lead sponsor
La Fondation contre le cancer, Belgique
Collaborator
